Small bowel adenocarcinoma

Wendum D., Svrcek M., Rigau V., Boelle P. Y., Sebbagh N., Parc R., Masliah J., Trugnan G., and Fle-jou J. F. (2003). COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Modem Pathol. 16 130-136. 

The majority (66%) of nonampullary small bowel adenocarcinomas are CK7-I-/CK20-I-, which differs from colorectal adenocarcinomas, which tend to be CK7-/CK20-I-. 

Enteropathy-associated, T-cell non-Hodgkin s lymphoma (EATL-NHL), the annual incidence of which is 0.5-1 per million people, is confined to patients with previously or concomitandy diagnosed CD and also complicates the refractory form of the enteropathy (SwiNSON et al. 1983). An increased risk of small bowel adenocarcinoma (an exceedingly rare malignancy with an annual incidence of 0.6-0.7 per 100,000 of the general population) has also been reported. 

---